Aptahem receives patent protection in USA for patent family 2
Aptahem AB (publ) announces today that the company has received patent protection in USA for patent family 2 from the United States Patent and Trademark Office (USPTO). The approval follows the previous preliminary approval from USPTO which was communicated on 30 June 2021.With USPTO’s approval of patent application 16/652,926, the protection of the company’s drug candidate Apta-1 within patent family 2 in the USA, U.S. Patent No. 11,110,115, is valid until the end of 2037. CEO Mikael Lindstam comments: ”I am very pleased to receive the final approval from USPTO, Issue Notification,